A viewer left a comment describing a 5–6 year history of urinary frequency and urgency. At first, medication was effective, but after stopping treatment for about a month, symptoms quickly returned. Over time, even when medications were resumed, the improvement became progressively weaker.
More recently, the patient developed dry mouth, severe constipation, and even blurred vision.
I explained that some of these symptoms are actually adverse effects of the medication itself. Continuing to tolerate side effects while persisting with the same drugs not only fails to resolve urinary frequency, but may also further worsen overall health.
First, we need to clarify an important point: not all cases of urinary frequency can be effectively treated with medication alone.
For example, in urethral stricture, urinary frequency and incomplete emptying occur because urine cannot pass through properly. In such cases, surgical intervention or urethral stent placement is often required to relieve the obstruction.
Similarly, in overactive bladder (OAB), approximately 30% of patients respond poorly to standard pharmacological therapy. In these cases, instead of relying solely on medication, it is more important to consider advanced treatment options.
Refractory Overactive Bladder (Refractory OAB)
Refractory OAB is defined as a condition in which symptoms do not significantly improve after:
8–12 weeks of behavioral therapy, or
4–8 weeks of pharmacological treatment with inadequate response or intolerance,
and persistent failure after switching medications.
Patients in this category are clinically classified as having refractory overactive bladder.
Increasing medication dosage or repeatedly switching drugs often only leads to worsening side effects, including:
Dry mouth
Constipation
Dry eyes
Blurred vision
Even urinary retention in severe cases
International clinical guidelines suggest that for medication-refractory OAB, neuromodulation therapies should be considered, such as:
Sacral Neuromodulation (SNM)
Posterior Tibial Nerve Stimulation (PTNS)
These treatments involve implanting or applying electrodes to deliver mild electrical impulses that modulate abnormal neural reflex pathways, thereby increasing bladder storage capacity and improving urinary symptoms.
Neurogenic Bladder
The situation is more complex in neurogenic bladder, which is caused by neurological diseases, spinal cord injury, or nerve damage following surgery or trauma.
It is characterized by dysfunction of the detrusor muscle and/or urethral sphincter, with the underlying pathology originating in the nervous system.
In such cases, medications that only target bladder smooth muscle activity are often insufficient.
Management frequently requires:
Intermittent or indwelling catheterization
Regular monitoring of post-void residual urine
Renal function surveillance
If there is evidence of impaired kidney function, timely interventions such as catheterization, urinary diversion (e.g., cystostomy), sacral neuromodulation, or even bladder augmentation surgery may be necessary to protect renal function.
Medication Options and Limitations
Commonly used medications include:
1. Antimuscarinic agents
(e.g., solifenacin, tolterodine)
These work by inhibiting detrusor overactivity and reducing urgency. However, they are frequently associated with:
Dry mouth
Constipation
2. β3-adrenergic agonists
(e.g., mirabegron)
These relax the detrusor smooth muscle and increase bladder storage capacity. Compared with antimuscarinics, they generally cause fewer anticholinergic side effects, but are often more expensive.
For elderly patients with cognitive impairment, drugs that have limited penetration of the blood-brain barrier (e.g., solifenacin) are preferred to minimize central nervous system effects.
The choice of medication should be individualized based on:
Age
Comorbidities
Side effect tolerance
Financial considerations
Blindly following medication regimens is not recommended.
Medication Withdrawal and Symptom Rebound
It is worth noting that long-term use of anticholinergic medications followed by abrupt discontinuation may lead to rebound worsening of symptoms, where urinary frequency and urgency become even more severe than before treatment.
The appropriate approach is gradual tapering under medical supervision, for example:
Reduce dosage by approximately 25% every two weeks
Gradually allow physiological adaptation
Then discontinue completely if appropriate
Final Key Point
If, after addressing all of the above factors, symptoms still do not improve adequately, further diagnostic evaluation is strongly recommended.
Effective treatment depends on identifying the correct underlying cause. Only by targeting the root pathology can an appropriate and personalized treatment plan be developed.
